4576 Stock Overview
A biotechnology company, focuses on discovery and development of various drugs.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
D. Western Therapeutics Institute, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥95.00 |
52 Week High | JP¥238.00 |
52 Week Low | JP¥85.00 |
Beta | 0.72 |
11 Month Change | 4.40% |
3 Month Change | -28.03% |
1 Year Change | -54.33% |
33 Year Change | -66.19% |
5 Year Change | -79.87% |
Change since IPO | -75.95% |
Recent News & Updates
Shareholder Returns
4576 | JP Biotechs | JP Market | |
---|---|---|---|
7D | 4.4% | 7.5% | 2.7% |
1Y | -54.3% | -7.7% | 18.6% |
Return vs Industry: 4576 underperformed the JP Biotechs industry which returned -7.7% over the past year.
Return vs Market: 4576 underperformed the JP Market which returned 21% over the past year.
Price Volatility
4576 volatility | |
---|---|
4576 Average Weekly Movement | 6.2% |
Biotechs Industry Average Movement | 7.6% |
Market Average Movement | 3.9% |
10% most volatile stocks in JP Market | 7.3% |
10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4576's share price has been volatile over the past 3 months.
Volatility Over Time: 4576's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 21 | Yuichi Hidaka | www.dwti.co.jp |
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. The company offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; DWR-2206, a regenerative medicine cell-product for bullous keratopathy; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. It is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; K-321 to treat fuch endothelial corneal dystrophy which is in Phase III clinical trials; and H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension.
D. Western Therapeutics Institute, Inc. Fundamentals Summary
4576 fundamental statistics | |
---|---|
Market cap | JP¥2.97b |
Earnings (TTM) | -JP¥1.03b |
Revenue (TTM) | JP¥442.00m |
6.9x
P/S Ratio-3.0x
P/E RatioIs 4576 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4576 income statement (TTM) | |
---|---|
Revenue | JP¥442.00m |
Cost of Revenue | JP¥37.00m |
Gross Profit | JP¥405.00m |
Other Expenses | JP¥1.44b |
Earnings | -JP¥1.03b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 09, 2024
Earnings per share (EPS) | -32.07 |
Gross Margin | 91.63% |
Net Profit Margin | -234.16% |
Debt/Equity Ratio | 103.7% |
How did 4576 perform over the long term?
See historical performance and comparison